COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study
JNCI Cancer Spectrum · 2026
DOI: 10.1093/jncics/pkag110 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Jérôme Doyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Antoine Lacassagne Cancer Center, Côte d'Azur University, Nice, France. Hauptthemen laut MEDLINE: Neoplasms, COVID-19, Thrombosis. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
COVID-19 has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched pre-pandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7 months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Antoine Lacassagne Cancer Center, Côte d'Azur University, Nice, France.
- Department of Gastroenterology, Centre Hospitalier Universitaire de Nice, Nice, France.
- Department of Epidemiology, Biostatistics and Health Data, Centre Antoine-Lacassagne, Côte d'Azur University, Nice, France.
- ICBMS-Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires, Equipe COSSBA UMR 5246, Lyon, France.
- Unité d'Explorations Fonctionnelles, Centre Hospitalier Universitaire de Nice, Côte d'Azur University, Nice, France.
- LP2M, Laboratoire de Physiomédecine Moléculaire, CNRS, Côte d'Azur University, Nice, France.
ORCID-Profile: Jérôme Doyen
Zitieren
APA
Doyen, J., Lacour, A., Schiappa, R., Seutin, E., Garrido, A., Loscos, T. P., & Doyen, D. (2026). COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag110
Vancouver
Doyen J, Lacour A, Schiappa R, Seutin E, Garrido A, Loscos TP, et al. COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag110
BibTeX
@article{Doyen2026,
author = {Doyen, Jérôme and Lacour, Alexandre and Schiappa, Renaud and Seutin, Eva and Garrido, Amanda and Loscos, Tanguy Pace and Doyen, Denis},
title = {COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study},
journal = {JNCI Cancer Spectrum},
year = {2026},
doi = {10.1093/jncics/pkag110}
}
EUVIMED